JP2004519454A5 - - Google Patents

Download PDF

Info

Publication number
JP2004519454A5
JP2004519454A5 JP2002554677A JP2002554677A JP2004519454A5 JP 2004519454 A5 JP2004519454 A5 JP 2004519454A5 JP 2002554677 A JP2002554677 A JP 2002554677A JP 2002554677 A JP2002554677 A JP 2002554677A JP 2004519454 A5 JP2004519454 A5 JP 2004519454A5
Authority
JP
Japan
Prior art keywords
dimethoxy
dihydro
quinazolin
group
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002554677A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004519454A (ja
JP4031363B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2001/014885 external-priority patent/WO2002053558A1/en
Publication of JP2004519454A publication Critical patent/JP2004519454A/ja
Publication of JP2004519454A5 publication Critical patent/JP2004519454A5/ja
Application granted granted Critical
Publication of JP4031363B2 publication Critical patent/JP4031363B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2002554677A 2001-01-02 2001-12-17 α−1A/Bアドレナリン作動性受容体拮抗薬としてのキナゾロン誘導体 Expired - Fee Related JP4031363B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25933701P 2001-01-02 2001-01-02
US32526701P 2001-09-27 2001-09-27
PCT/EP2001/014885 WO2002053558A1 (en) 2001-01-02 2001-12-17 Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists

Publications (3)

Publication Number Publication Date
JP2004519454A JP2004519454A (ja) 2004-07-02
JP2004519454A5 true JP2004519454A5 (cg-RX-API-DMAC10.html) 2005-05-26
JP4031363B2 JP4031363B2 (ja) 2008-01-09

Family

ID=26947245

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002554677A Expired - Fee Related JP4031363B2 (ja) 2001-01-02 2001-12-17 α−1A/Bアドレナリン作動性受容体拮抗薬としてのキナゾロン誘導体

Country Status (16)

Country Link
EP (1) EP1363899B1 (cg-RX-API-DMAC10.html)
JP (1) JP4031363B2 (cg-RX-API-DMAC10.html)
KR (1) KR100554813B1 (cg-RX-API-DMAC10.html)
CN (1) CN1237060C (cg-RX-API-DMAC10.html)
AR (1) AR035775A1 (cg-RX-API-DMAC10.html)
AT (1) ATE295362T1 (cg-RX-API-DMAC10.html)
BR (1) BR0116662A (cg-RX-API-DMAC10.html)
CA (1) CA2432578C (cg-RX-API-DMAC10.html)
DE (1) DE60110844T2 (cg-RX-API-DMAC10.html)
ES (1) ES2241891T3 (cg-RX-API-DMAC10.html)
MX (1) MXPA03005854A (cg-RX-API-DMAC10.html)
PA (1) PA8536001A1 (cg-RX-API-DMAC10.html)
PE (1) PE20020735A1 (cg-RX-API-DMAC10.html)
UY (1) UY27109A1 (cg-RX-API-DMAC10.html)
WO (1) WO2002053558A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200305038B (cg-RX-API-DMAC10.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0206033D0 (en) 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy
GB0225908D0 (en) * 2002-11-06 2002-12-11 Pfizer Ltd Treatment of female sexual dysfunction
JP2009513502A (ja) * 2003-07-02 2009-04-02 エフ.ホフマン−ラ ロシュ アーゲー アリールアミン置換キナゾリノン化合物
EP1644343B1 (en) * 2003-07-02 2007-07-04 F. Hoffmann-La Roche Ag 5-substituted quinazolinone derivatives
TW200530235A (en) 2003-12-24 2005-09-16 Renovis Inc Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
US7793137B2 (en) 2004-10-07 2010-09-07 Cisco Technology, Inc. Redundant power and data in a wired data telecommunincations network
FR2870846B1 (fr) 2004-05-25 2006-08-04 Sanofi Synthelabo Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
US20060128710A1 (en) * 2004-12-09 2006-06-15 Chih-Hung Lee Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
US7402596B2 (en) 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
JP5198256B2 (ja) * 2005-05-04 2013-05-15 エボテク エージー 縮合複素環式化合物、並びにそれらの組成物及び使用
EP1928237A4 (en) 2005-09-02 2011-03-09 Abbott Lab NEW HETEROCYCLES BASED ON IMIDAZO
US20090163571A1 (en) * 2005-11-24 2009-06-25 Kissei Pharmaceutical Co., Ltd Pharmaceutical for use in the treatment of ureterolithiasis
WO2008123963A1 (en) 2007-04-02 2008-10-16 Renovis, Inc. Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof
US8076345B2 (en) 2007-04-17 2011-12-13 Evotec Ag 2-cyanophenyl-7,8-dihydro-5H-pyrido[4,3-d]pyrimidine compounds, compositions and uses thereof
US8859538B2 (en) 2007-06-21 2014-10-14 Cara Therapeutics, Inc. Uses of substituted imidazoheterocycles
EA201000046A1 (ru) 2007-06-21 2011-02-28 Кара Терапеутикс, Инк. Замещенные имидазогетероциклы
CN101417999A (zh) * 2007-10-25 2009-04-29 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用
UY32776A (es) 2009-07-09 2011-02-28 Irm Llc Compuestos de imidazopirazinas sustituidas para el tratamiento de enfermedades parasitarias,composiciones farmacéuticas que los contienen y aplicación.
WO2015018797A2 (en) * 2013-08-05 2015-02-12 Haplogen Gmbh Antiviral compounds
GB201321748D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
EP3083628B1 (en) * 2013-12-20 2019-08-07 Esteve Pharmaceuticals, S.A. Fused imidazolyl derivatives, their preparation and use as medicaments
ES2863873T3 (es) 2016-05-18 2021-10-11 Mirati Therapeutics Inc Inhibidores de KRAS G12C
CN107434786B (zh) * 2016-05-27 2025-11-18 广东东阳光药业股份有限公司 苯并咪唑化合物及其制备方法
CN110691597A (zh) 2017-04-24 2020-01-14 诺华股份有限公司 2-氨基-1-(2-(4-氟苯基)-3-(4-氟苯基氨基)-8,8-二甲基-5,6-二氢咪唑并[1,2-a]吡嗪-7(8H)-基)乙酮及其组合的治疗方案
US10647715B2 (en) 2017-11-15 2020-05-12 Mirati Therapeutics, Inc. KRas G12C inhibitors
CA3082579A1 (en) 2017-11-15 2019-05-23 Mirati Therapeutics, Inc. Kras g12c inhibitors
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
US12208099B2 (en) 2018-09-10 2025-01-28 Mirati Therapeutics, Inc. Combination therapies
SMT202500028T1 (it) 2018-09-10 2025-03-12 Mirati Therapeutics Inc Terapie combinate
AU2019338207B2 (en) 2018-09-10 2025-01-02 Mirati Therapeutics, Inc. Combination therapies
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
US12377101B2 (en) 2018-12-05 2025-08-05 Mirati Therapeutics, Inc. Combination therapies
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
US20230096028A1 (en) * 2019-03-01 2023-03-30 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
CN114761012B (zh) 2019-09-24 2025-03-21 米拉蒂治疗股份有限公司 组合疗法
CN110950886A (zh) * 2019-12-13 2020-04-03 苏州莱克施德药业有限公司 一种合成1-甲基-咪唑-2-甲酸甲酯衍生物的方法
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
US12655160B2 (en) 2020-08-04 2026-06-16 Mirati Therapeutics, Inc. KRAS G12D inhibitors
EP4210833A4 (en) 2020-09-11 2024-09-11 Mirati Therapeutics, Inc. CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
EP4216951B1 (en) 2020-09-22 2026-04-01 Mirati Therapeutics, Inc. Kras g12d inhibitors
EP4262807A4 (en) 2020-12-15 2025-04-23 Mirati Therapeutics, Inc. Azachinazoline pan-KRAS inhibitors
WO2022133038A1 (en) 2020-12-16 2022-06-23 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
WO2023057985A1 (en) * 2021-10-08 2023-04-13 Vrise Therapeutics, Inc. Small molecules for treatement of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1062357A (en) * 1965-03-23 1967-03-22 Pfizer & Co C Quinazolone derivatives
US4044136A (en) * 1972-09-09 1977-08-23 Pfizer Inc. Aminoquinazoline therapeutic agents
DE2757925A1 (de) * 1977-12-24 1979-06-28 Bayer Ag Diazacyclo-1.2.4-benzothiadizine, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
GB9526546D0 (en) * 1995-12-23 1996-02-28 Pfizer Ltd Compounds useful in therapy
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
AU3555200A (en) * 1999-03-17 2000-10-04 F. Hoffmann-La Roche Ag Oxazolone derivatives and their use as alpha-1 adrenoreceptor modulators

Similar Documents

Publication Publication Date Title
JP4031363B2 (ja) α−1A/Bアドレナリン作動性受容体拮抗薬としてのキナゾロン誘導体
US8841299B2 (en) Substituted pyrrolo[1,2-a]pyrazines as tankyrase inhibitors
FI78296B (fi) Foerfarande foer framstaellning av terapeutiskt aktiva 2-substituerade 4-amino-6,7-dimetoxikinolinderivat.
US7608622B2 (en) Imidazo[4,5-b]pyrazinone inhibitors of protein kinases
US6423716B1 (en) Nitrogenous heterocyclic compounds
JP2020519589A5 (cg-RX-API-DMAC10.html)
JP2003530387A (ja) キナゾリン化合物
RU2005117342A (ru) Новые аминозамещенные производные дигидропиримидо [4,5d]-пиримидинона, их получение и применение в качестве фармацевтических средств
HUP0400828A2 (hu) Kondenzált heterociklikus aminopirimidinek, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
AU2016425880B2 (en) Naphthyridine compound, pharmaceutical composition and use thereof
CA2450724A1 (en) Quinazoline and pyrido¬2,3-d|pyrimidine inhibitors of phosphodiesterase (pde) 7
JP2004521892A (ja) (ハロ−ベンゾカルボニル)複素環縮合フェニル系p38キナーゼ阻害剤
WO2008141843A1 (en) Novel sulphoximine-substituted quinazoline and quinazoline derivatives as kinase inhibitors
KR20140021629A (ko) 단백질 키나제 저해제
MXPA05002743A (es) Derivados arilpiperazina de benzodioxanos con heterociclos fusionados antidepresivos.
US7091200B2 (en) Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
KR20220090443A (ko) 헤테로아릴 유도체 화합물 및 이의 용도
TWI428342B (zh) 新穎二氫-唑并苯并二氮雜酮化合物、其製備方法及含其之醫藥組合物
WO1999043679A1 (en) Imidazoquinazoline derivatives
JP3024013B2 (ja) フルオロエチルカンプトテシン誘導体
KR101917264B1 (ko) 5-ht7 수용체 조절제로 작용하는 아제핀 유도체
AU780528B2 (en) Fused azepinone cyclin dependent kinase inhibitors
AU2002234586A1 (en) Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists
JP2023503875A (ja) 新規なトリアゾロピリジン誘導体およびこれを含む薬学組成物
JPWO1999051582A1 (ja) 含窒素複素環化合物